These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 21598311)
1. Extensive aspartoacylase expression in the rat central nervous system. Moffett JR; Arun P; Ariyannur PS; Garbern JY; Jacobowitz DM; Namboodiri AM Glia; 2011 Oct; 59(10):1414-34. PubMed ID: 21598311 [TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical localization of aspartoacylase in the rat central nervous system. Madhavarao CN; Moffett JR; Moore RA; Viola RE; Namboodiri MA; Jacobowitz DM J Comp Neurol; 2004 May; 472(3):318-29. PubMed ID: 15065127 [TBL] [Abstract][Full Text] [Related]
3. Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS. Traka M; Wollmann RL; Cerda SR; Dugas J; Barres BA; Popko B J Neurosci; 2008 Nov; 28(45):11537-49. PubMed ID: 18987190 [TBL] [Abstract][Full Text] [Related]
4. Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease. Klugmann M; Leichtlein CB; Symes CW; Serikawa T; Young D; During MJ Mol Ther; 2005 May; 11(5):745-53. PubMed ID: 15851013 [TBL] [Abstract][Full Text] [Related]
5. Myelin lesion in the aspartoacylase (Aspa) knockout rat, an animal model for Canavan disease. Takeda S; Hoshiai R; Tanaka M; Izawa T; Yamate J; Kuramoto T; Kuwamura M Exp Anim; 2024 Jul; 73(3):347-356. PubMed ID: 38538326 [TBL] [Abstract][Full Text] [Related]
7. Downregulation of aspartoacylase during the progression of myelin breakdown in the dmy mutant rat with mitochondrial magnesium channel MRS2 defect. Kuwamura M; Tanimura S; Hasegawa Y; Hoshiai R; Moriyama Y; Tanaka M; Takenaka S; Nagayoshi H; Izawa T; Yamate J; Kuramoto T; Serikawa T Brain Res; 2019 Sep; 1718():169-175. PubMed ID: 31100216 [TBL] [Abstract][Full Text] [Related]
8. N-Acetylaspartate Synthase Deficiency Corrects the Myelin Phenotype in a Canavan Disease Mouse Model But Does Not Affect Survival Time. Maier H; Wang-Eckhardt L; Hartmann D; Gieselmann V; Eckhardt M J Neurosci; 2015 Oct; 35(43):14501-16. PubMed ID: 26511242 [TBL] [Abstract][Full Text] [Related]
9. Renewal of oligodendrocyte lineage reverses dysmyelination and CNS neurodegeneration through corrected N-acetylaspartate metabolism. Lotun A; Li D; Xu H; Su Q; Tuncer S; Sanmiguel J; Mooney M; Baer CE; Ulbrich R; Eyles SJ; Strittmatter L; Hayward LJ; Gessler DJ; Gao G Prog Neurobiol; 2023 Jul; 226():102460. PubMed ID: 37149081 [TBL] [Abstract][Full Text] [Related]
10. N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Moffett JR; Ross B; Arun P; Madhavarao CN; Namboodiri AM Prog Neurobiol; 2007 Feb; 81(2):89-131. PubMed ID: 17275978 [TBL] [Abstract][Full Text] [Related]
11. Metabolic acetate therapy improves phenotype in the tremor rat model of Canavan disease. Arun P; Madhavarao CN; Moffett JR; Hamilton K; Grunberg NE; Ariyannur PS; Gahl WA; Anikster Y; Mog S; Hallows WC; Denu JM; Namboodiri AM J Inherit Metab Dis; 2010 Jun; 33(3):195-210. PubMed ID: 20464498 [TBL] [Abstract][Full Text] [Related]
12. Involvement of aspartoacylase in tremor expression in rats. Nishitani A; Tanaka M; Shimizu S; Kunisawa N; Yokoe M; Yoshida Y; Suzuki T; Sakuma T; Yamamoto T; Kuwamura M; Takenaka S; Ohno Y; Kuramoto T Exp Anim; 2016 Jul; 65(3):293-301. PubMed ID: 27026062 [TBL] [Abstract][Full Text] [Related]
13. N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase. Francis JS; Wojtas I; Markov V; Gray SJ; McCown TJ; Samulski RJ; Bilaniuk LT; Wang DJ; De Vivo DC; Janson CG; Leone P Neurobiol Dis; 2016 Dec; 96():323-334. PubMed ID: 27717881 [TBL] [Abstract][Full Text] [Related]
14. Loss of central auditory processing in a mouse model of Canavan disease. von Jonquieres G; Froud KE; Klugmann CB; Wong AC; Housley GD; Klugmann M PLoS One; 2014; 9(5):e97374. PubMed ID: 24826990 [TBL] [Abstract][Full Text] [Related]
15. Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy. von Jonquieres G; Spencer ZHT; Rowlands BD; Klugmann CB; Bongers A; Harasta AE; Parley KE; Cederholm J; Teahan O; Pickford R; Delerue F; Ittner LM; Fröhlich D; McLean CA; Don AS; Schneider M; Housley GD; Rae CD; Klugmann M Acta Neuropathol; 2018 Jan; 135(1):95-113. PubMed ID: 29116375 [TBL] [Abstract][Full Text] [Related]
17. Canavan disease and the role of N-acetylaspartate in myelin synthesis. Namboodiri AM; Peethambaran A; Mathew R; Sambhu PA; Hershfield J; Moffett JR; Madhavarao CN Mol Cell Endocrinol; 2006 Jun; 252(1-2):216-23. PubMed ID: 16647192 [TBL] [Abstract][Full Text] [Related]
18. Effects of AAV-2-mediated aspartoacylase gene transfer in the tremor rat model of Canavan disease. McPhee SW; Francis J; Janson CG; Serikawa T; Hyland K; Ong EO; Raghavan SS; Freese A; Leone P Brain Res Mol Brain Res; 2005 Apr; 135(1-2):112-21. PubMed ID: 15857674 [TBL] [Abstract][Full Text] [Related]
19. The pathogenesis of, and pharmacological treatment for, Canavan disease. Wei H; Moffett JR; Amanat M; Fatemi A; Tsukamoto T; Namboodiri AM; Slusher BS Drug Discov Today; 2022 Sep; 27(9):2467-2483. PubMed ID: 35636725 [TBL] [Abstract][Full Text] [Related]
20. NAAG synthetase deficiency has only low influence on pathogenesis in a Canavan disease mouse model. Becker I; Wang-Eckhardt L; Eckhardt M J Inherit Metab Dis; 2024 Mar; 47(2):230-243. PubMed ID: 38011891 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]